J&J speeds into new bladder cancer trial
The company takes another project from Taris into phase 3 as it chases a $5bn market.
CG gets money before data
CG Oncology and Arrivent pull off US flotations, and both offer speculative investment cases.
ASCO-GU – Opdivo's approval might have scuppered Keynote-123
The Bristol drug's availability for adjuvant bladder cancer threw Keynote-123 out of kilter.
KRAS crowding continues
Another KRAS G12D inhibitor hits the clinic, while Zai Lab hopes to banish the spectre of Rova-T.
Bicycle aims to follow in Padcev’s slipstream
A study to back accelerated approval is to start next year, but the prospect of seeing a fully greenlit Padcev before then looms large.
